CADTH Canadian Drug Expert Committee recommendation : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD. Safinamide (Onstryv -- Valeo Pharma Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Cost effectiveness.

Physical Description:

1 online resource

Edition:

First edition.

Place of Publication:

Ottawa (ON) : CADTH, 2020.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that safinamide should not be reimbursed as add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic PD in patients experiencing "OFF" episodes while on a stable dose of levodopa.

Notes:

Description based on publisher supplied metadata and other sources.